Document:

<PAGE>

                                 AMENDMENT NO. 2
                                       TO
                          SECURITIES PURCHASE AGREEMENT

         THIS AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT is entered
into as of the [16TH] day of April 2001 (the "Amendment") by and among the
undersigned investors (each an "Investor" and together the "Investors") and
Interactive Telesis Inc., a Delaware corporation (the "Company").

         WHEREAS, the parties entered into that certain Securities Purchase
Agreement dated June 12, 2000 (as amended on August 29, 2000 by that certain
Amendment No. 1 to Securities Purchase Agreement, the "Common Stock Purchase
Agreement"), pursuant to which the Company agreed to issue and sell to the
Investors, and the Investors agreed to purchase from the Company up to
$4,500,000 of the Company's Common Stock and to receive in connection therewith
certain Repricing Rights and Warrants to purchase shares of the Company's Common
Stock; and

         WHEREAS, simultaneous with the execution of this Amendment, the parties
hereto are entering into a Series B Preferred Stock Purchase Agreement (the
"Series B Purchase Agreement"), pursuant to which the Company agrees to issue
and sell to the Investors, and the Investors agree to purchase from the Company,
$250,000 of the Company's Series B Preferred Stock, $0.001 par value per share
(the "Series B Preferred Stock"), and to receive warrants to purchase shares of
the Company's Series B Preferred Stock (the "Series B Warrants").

         WHEREAS, in connection with and as consideration for entering into the
Series B Purchase Agreement, the parties desire herein to amend the Common Stock
Purchase Agreement as provided herein.

         NOW, THEREFORE, in consideration of the mutual promises,
representations, warranties, covenants and conditions set forth in this
Amendment and the Series B Purchase Agreement, the parties hereto agree as
follows:

         1. DEFINED TERMS. Terms that are used herein with initial capital
letters and are not otherwise defined herein will have the meanings given to
them in the Common Stock Purchase Agreement.

         2. AMENDMENT TO ARTICLE I. Effective upon the Closing (as defined
in the Series B Purchase Agreement) [AND RETROACTIVE WITH RESPECT TO ANY
CONVERSIONS EFFECTED BY THE INVESTORS ON FEBRUARY 1, 2001 AND FEBRUARY 13,
2001], the definition of the following term contained in Article I of the
Common Stock Purchase Agreement shall be amended and restated in its entirety
as follows:

         "AVERAGE MARKET PRICE" for any Exercise Date means ninety percent (90%)
         of the average of the Market Price on each of the two (2) trading days
         having the lowest Market Prices, whether or not consecutive, during the
         period of thirty (30) consecutive trading

<PAGE>

         days ending on the trading day prior to such date. Average Market
         Price shall be reduced by 5% if the Company receives notice of
         delisting from its Principal Market."

         [THE COMPANY AGREES TO ISSUE ADDITIONAL SHARES OF ITS COMMON STOCK TO
THE INVESTORS WITHIN 5 DAYS FROM THE DATE HEREOF TO GIVE EFFECT TO THIS
AMENDMENT WITH RESPECT TO THE CONVERSIONS EFFECTED ON FEBRUARY 1, 2001 AND
FEBRUARY 13, 2001.]

         3. AMENDMENT TO SECTION 2.2(h)(C)(C). Effective upon the Closing (as
defined in the Series B Purchase Agreement), Section 2.2(h)(C)(C) of the Common
Stock Purchase Agreement shall be amended and restated in its entirety to read
as follows:

             "(C)     any remaining Repricing Rights then unexercised shall
                      expire twenty four (24) months after the applicable
                      Effective Date; provided, however, this expiration
                      date shall be extended for a period of time equal to
                      any delay in the Registration Statement going
                      effective after the Scheduled Effective Date (except
                      for delays caused primarily by the Investors) and for
                      the length of any suspensions after the Effective
                      Date."

         4. COVENANTS OF THE COMPANY. For purposes of this Section 4, terms used
with initial capital letters shall have the meanings ascribed to such terms in
the Series B Purchase Agreement.

                  (a) LIMITATION ON FUTURE FINANCING. The Company agrees that it
will not sell or enter into any agreement to sell any of its securities or incur
any indebtedness outside the ordinary course of business until six (6) months
after the Closing Date, except for any sales (i) pursuant to any presently
existing employee benefit plan which plan has been approved by the Company's
stockholders, (ii) pursuant to any compensatory plan for a full-time employee or
key consultant, (iii) with the prior approval of holders of a majority of the
Conversion Shares then outstanding, which will not be unreasonably withheld, in
connection with a strategic partnership or other business transaction, the
principal purpose of which is not financing the Company's business operations,
(iv) of Common Stock resulting in gross proceeds to the Company of not less than
$5 million at a fixed price per share not less than the per share Purchase Price
at the Closing (as adjusted for any stock splits, dividends or similar events),
or (v) made to Hambrecht & Quist Guaranty Finance, LLC ("H&QGF") pursuant to the
existing terms of the Loan and Security Agreement between H&QGF and the Company
dated November 21, 2000 (as amended on March 30, 2001), or any warrants issued
in connection therewith.

                  (b) PROXY STATEMENT. If required either now or later by the
rules and regulations of the Principal Market or otherwise, upon the request of
the Investors, the Company shall provide each stockholder entitled to vote at
the next meeting of stockholders of the Company, which shall be not later than
90 days from the date of such request (the "STOCKHOLDER MEETING DEADLINE"), a
proxy statement, which has been previously reviewed by the Investors and a
counsel of their choice, soliciting each such stockholder's affirmative vote at
such stockholder meeting for approval of the Company's issuance of all of the
Purchased Shares, Warrant Shares and Conversion Shares in excess of any
limitation or cap imposed by the Principal Market or otherwise, and the Company
shall use its best efforts to solicit its stockholders' approval of such
issuance of the Securities and cause the Board of Directors of the Company to
recommend to the

                                       2
<PAGE>

stockholders that they approve such proposal. If the Company fails to hold a
meeting of its stockholders by the Stockholder Meeting Deadline (unless such
failure is the result solely of the actions of the Investors), then, as
partial relief (which remedy shall not be exclusive of any other remedies
available at law or in equity), the Company shall pay to each holder of
Conversion Shares (assuming the exercise of all Warrants and the conversion
of all Series B Preferred Stock or other securities) an amount in cash per
share equal to 2.5% of the Purchase Price applicable to such share per month
until the stockholder meeting is held (pro rated for partial months). The
Company shall make the payments referred to in the immediately preceding
sentence within five days of the earlier of (I) the holding of the meeting of
the Company's stockholders and (II) the last day of each 30-day period
beginning on the day after the Stockholder Meeting Deadline. In the event the
Company fails to make such payments in a timely manner, such payments shall
bear interest at the rate of 2.5% per month (pro rated for partial months)
until paid in full.

                  (c) TRANSACTIONS WITH AFFILIATES. So long as (i) there are
Warrants outstanding or (ii) any Investor owns Purchased Shares and/or Warrant
Shares and/or Conversion Shares with an aggregate market value equal to or
greater than $125,000, the Company shall not, and shall cause each of its
Subsidiaries not to, enter into, amend, modify or supplement, or permit any
Subsidiary to enter into, amend, modify or supplement, any agreement,
transaction, commitment or arrangement with any of its or any Subsidiary's
officers, directors, persons who were officers or directors at any time during
the previous two years, stockholders who beneficially own 5% or more of the
Common Stock, or affiliates or with any individual related by blood, marriage or
adoption to any such individual or with any entity in which any such entity or
individual owns a 5% or more beneficial interest (each, a "RELATED PARTY"),
except for (a) customary employment arrangements and benefit programs on
reasonable terms, (b) any agreement, transaction, commitment or arrangement on
an arm's-length basis on terms no less favorable than terms which would have
been obtainable from a person other than such Related Party, or (c) any
agreement, transaction, commitment or arrangement which is approved by a
majority of the disinterested directors of the Company. For purposes hereof, any
director who is also an officer of the Company or any Subsidiary of the Company
shall not be a disinterested director with respect to any such agreement,
transaction, commitment or arrangement. "AFFILIATE" for purposes of this Section
means, with respect to any person or entity, another person or entity that,
directly or indirectly, (i) has a 5% or more equity interest in that person or
entity, (ii) has 5% or more common ownership with that person or entity, (iii)
controls that person or entity, or (iv) shares common control with that person
or entity. "CONTROL" or "CONTROLS" for purposes hereof means that a person or
entity has the power, direct or indirect, to conduct or govern the policies of
another person or entity.

                  (d) RIGHT OF FIRST REFUSAL. Subject to Section 4(a), the
Company shall not sell any of its securities to Persons other than the Investors
during the period commencing on the date hereof and ending one year after the
Closing Date unless the Company shall first have satisfied its obligations under
this Section 4(d).

                           (i)  If the Company receives a written offer from any
Person or group of Persons other than the Investors to purchase any of the
Company's securities, the Company shall give the Investors a written notice of
such offer stating the type, terms, and purchase price of such securities and
the other material terms and conditions of the sale of such securities and

                                       3
<PAGE>

attaching a copy of any offer signed by the Person or Persons making such offer.

                           (ii)  The Investors shall have the right to purchase
all or any part of such securities on the same terms and conditions as are set
forth in the Company's written notice. Each Investor may exercise its right to
purchase such securities by giving a written notice of exercise to the Company
within seven (7) days after such Investor's receipt of the Company's notice.
Each Investor shall have the right to purchase such securities pro rata in
accordance with the number of shares of Common Stock (assuming the exercise of
all warrants and the conversion of all Preferred Stock or other securities) that
it has purchased under this Agreement and the Purchase Agreement. Each Investor
may also notify the Company that it will purchase its pro rata share of any such
securities not purchased by the other Investors.

                           (iii) If the Investors shall not have exercised their
rights to purchase all of such securities, then the Company shall have the
right to sell all securities not subscribed by the Investors on the same terms
and conditions as those set forth in the Company's notice. If the Company shall
not have sold all such securities within 30 days after the expiration of the
7-day period in subsection 4(d)(ii) above, then the Company shall not sell any
such securities unless it first offers to sell such securities to the Investors
in accordance with the procedures set forth in this Section 4(d).

                  (e) SUSPENSION OF TRADING. In addition any other remedies
which the Investors have under the Series B Purchase Agreement and under
applicable law, for each business day on which trading in the shares of Common
Stock is suspended or prohibited on the Principal Market, the Company shall pay
the Investors an amount equal to 0.2% of the product of (1) the number of shares
of Common Stock (assuming the exercise of all warrants and the conversion of all
Preferred Stock or other securities) then held by the Investors and (2) the
closing sale price of the Common Stock on the trading day prior to such
suspension or prohibition. The cumulative amount of such amounts which have
accrued shall be paid by the Company to the Investors every seven (7) business
days after the date of such suspension or prohibition.

         5. EFFECT OF AMENDMENT. The provisions of the Common Stock Purchase
Agreement are amended and modified by the provisions of this Amendment. If any
provisions of the Common Stock Purchase Agreement are materially different from
or inconsistent with any of the provisions of this Amendment, the provisions of
this Amendment shall control, and the provisions of the Common Stock Purchase
Agreement shall, to the extent of such difference or inconsistency, be deemed to
be amended and modified.

         6. SINGLE AGREEMENT. This Amendment and the Common Stock Purchase
Agreement, as amended and modified by the provisions of this Amendment, shall
constitute and be construed as a single agreement.

                                       4
<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused this
Amendment No. 2 to Securities Purchase Agreement to be executed by the
undersigned, thereunto duly authorized, as of the date first set forth above.
<TABLE>
<S>                                               <C>
                                                   COMPANY:

                                                   INTERACTIVE TELESIS INC.

                                                   By:_____________________________________

                                                   Name:___________________________________

                                                   INVESTORS:

Address:                                           BH Capital Investments, L.P.
175 Bloor Street East, 7th Floor, South Tower      By: HB and Co., Inc. its General Partner
Toronto, Ontario Canada M4W 3R8
Fax: 416-929-5314
                                                   By:_____________________________________
                                                   Name: Henry Brachfeld
                                                         Authorized Signatory

Address:                                           Excalibur Limited Partnership
33 Prince Arthur Avenue                            By: Excalibur Capital Management, Inc.
Toronto, Ontario, Canada M5R 1B2                       its General Partner
Fax: 416-964-8868

                                                   By:_____________________________________
                                                   Name: William Hechter, President
</TABLE>

                                       5<PAGE>

NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")
OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON AN EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS.
NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF MAY BE SOLD,
PLEDGED, TRANSFERRED, ENCUMBERED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO
REGULATION S OF THE SECURITIES ACT, AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER
THE PROVISIONS OF THE SECURITIES ACT.

                    SERIES B PREFERRED STOCK PURCHASE WARRANT

              To Purchase 7,500 Shares of Series B Preferred Stock

                            INTERACTIVE TELESIS INC.

         THIS CERTIFIES that, for value received, BH CAPITAL INVESTMENTS, L.P.
(the "HOLDER"), is entitled, upon the terms and subject to the conditions
hereinafter set forth, at any time on or after the date hereof (the "INITIAL
EXERCISE DATE") and on or prior to the close of business on the date ending
three (3) years from the Initial Exercise Date (the "TERMINATION DATE"), but not
thereafter, to subscribe for and purchase from Interactive Telesis Inc., a
corporation incorporated in Delaware (the "COMPANY"), up to SEVEN THOUSAND FIVE
HUNDRED (7,500) shares (the "WARRANT SHARES") of Series B Preferred Stock,
$0.001 par value, of the Company (the "Series B Preferred Stock"), which shares
are initially convertible into shares of Common Stock, $0.001 par value, of the
Company (the "Common Stock") on a 10-for-1 basis. The purchase price of one
share of Series B Preferred Stock (the "EXERCISE PRICE") under this Warrant
shall be $5.50. Capitalized terms used and not otherwise defined herein shall
have the meanings set forth for such terms in the Series B Preferred Stock
Purchase Agreement dated April ___, 2001, as amended, between the Company and
the Investors thereto (the "PURCHASE AGREEMENT"). The Exercise Price and the
number of shares for which the Warrant is exercisable shall be subject to
adjustment as provided herein and under the Purchase Agreement. In the event of
any conflict between the terms of this Warrant and the Purchase Agreement, the
Purchase Agreement shall control.

                  1. TITLE TO WARRANT. Prior to the Termination Date and subject
to compliance with applicable laws, this Warrant and all rights hereunder are
transferable, in whole or in part, at the office or agency of the Company by the
Holder hereof in person or by duly authorized attorney, upon surrender of this
Warrant together with the Assignment Form annexed hereto properly endorsed.

                  2. AUTHORIZATION OF SHARES. The Company covenants that all
shares of Series B Preferred Stock which may be issued upon the exercise of
rights represented by this Warrant and all shares of Common Stock issuable upon
exercise of the Series B Preferred Stock will, upon exercise of the rights
represented by this Warrant and conversion of the Series B Preferred Stock, be
duly authorized, validly issued, fully paid and nonassessable and free from all
taxes, liens and charges in respect of the issue thereof (other than taxes in
respect of any transfer occurring contemporaneously with such issue).

<PAGE>

                  3. EXERCISE OF WARRANT.

                           (a) Except as provided in Sections 3(b), 3(c) or 4
herein, exercise of the purchase rights represented by this Warrant may be made
at any time or times on or after the Initial Exercise Date, and before the close
of business on the Termination Date by the surrender of this Warrant and the
Notice of Exercise Form annexed hereto duly executed, at the office of the
Company (or such other office or agency of the Company as it may designate by
notice in writing to the registered Holder hereof at the address of such Holder
appearing on the books of the Company) and upon payment of the Exercise Price of
the shares thereby purchased by wire transfer or cashier's check drawn on a
United States bank, the Holder of this Warrant shall be entitled to receive a
certificate for the number of shares of Series B Preferred Stock so purchased.
This Warrant may also be exercised in whole or in part by means of a "cashless
exercise" by tendering this Warrant to the Company to receive a number of shares
of Series B Preferred Stock equal in Market Value to the difference between the
Market Value of the shares of Common Stock issuable upon such exercise of this
Warrant and conversion of the Series B Preferred Stock and the total cash
exercise price of that part of the Warrant being exercised. "MARKET VALUE" for
this purpose shall be the closing price of the Common Stock as reported by
Bloomberg L.P. on the date of such cashless exercise. Certificates for shares
purchased hereunder shall be delivered to the Holder hereof within three (3)
trading days after the date on which this Warrant shall have been exercised as
aforesaid. This Warrant shall be deemed to have been exercised and such
certificate or certificates shall be deemed to have been issued, and the Holder
or any other person so designated to be named therein shall be deemed to have
become the Holder of record of such shares for all purposes, as of the date the
Warrant has been exercised by payment to the Company of the Exercise Price and
all taxes required to be paid by the Holder, if any, pursuant to Section 5 prior
to the issuance of such shares, have been paid. If this Warrant shall have been
exercised in part, the Company shall, at the time of delivery of the certificate
or certificates representing Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased shares of Series
B Preferred Stock called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant.

                           (b) Anything in Section 3(a) to the contrary
notwithstanding, in no event shall the Holder be entitled to exercise this
Warrant if, upon giving effect to such exercise, the Holder and its "AFFILIATES"
(as defined in Rule 405 under the Securities Act) would beneficially own an
aggregate number of shares of Common Stock that would exceed 9.9% of the
outstanding shares of the Common Stock following such exercise. For purposes of
this Section 3(b), the aggregate number of shares of Common Stock beneficially
owned by the Holder and its affiliates shall include the number of shares of
Common Stock issuable upon exercise of the Warrants and conversion of the Series
B Preferred Stock with respect to which the determination is being made, but
shall exclude the number of shares of Common Stock which would be issuable upon
exercise or conversion of the unexercised or unconverted portion of any other
Securities of the Company (including, without limitation, any Repricing Rights
or other warrants), subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder and its
affiliates. Except as set forth in the preceding sentence, for purposes of this
Section 3(b), beneficial ownership shall be calculated in accordance with
Section 13(d) of the Securities Act. For purposes of this Section 3(b), in
determining the number of outstanding shares Common Stock the Holder may rely on
the number of outstanding shares of Common Stock as reflected in (1) the
Company's most recent quarterly or annual filing with the SEC, as the case may
be, (2) a more recent public announcement by the Company or (3) any other notice
by the Company or its transfer agent setting forth the number of shares of
Common Stock outstanding. For any reason at any time, upon the written or oral
request of the Holder, the Company shall immediately confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In
any case, the number of outstanding shares Common Stock shall be determined
after giving effect to exercises of Repricing Rights and Warrants by the Holder
since the date as of which such number of outstanding shares of Common Stock was
reported. To the extent that the limitation contained in this Section 3(b)
applies, the

                                       2
<PAGE>

determination of whether this Warrant is exercisable (in relation to other
Securities owned by the Holder) shall be in the sole discretion of the
Holder, and the exercise of this Warrant shall be deemed to be the Holder's
determination of whether this Warrant is exercisable (in relation to other
Securities owned by the Holder), subject to such aggregate percentage
limitation, and the Company shall have no obligation or right to verify or
confirm the accuracy of such determination. Nothing contained herein shall be
deemed to restrict the right of the Holder to exercise this Warrant at such
time as such exercise will not violate the provisions of this Section. The
Holder may waive the provisions of this Section 3(b) as to itself (and solely
as to itself) upon not less than 75 days' prior notice to the Company, and
the provisions of this Section 3(b) shall continue to apply until such 75th
day (or such later date as may be specified in such notice of waiver). No
exercise in violation of this Section, but otherwise in accordance with this
Warrant, shall affect the status of the Series B Preferred Stock issued upon
such exercise as validly issued, fully-paid and nonassessable.

                           (c) Notwithstanding any other provision herein, the
Company shall not be obligated to issue any shares of Series B Preferred Stock
upon exercise of this Warrant if the issuance of such shares of Series B
Preferred Stock would exceed any cap or limitation on the number of shares (the
"EXCHANGE CAP") imposed by the rules or regulations of the Principal Market, if
and to the extent applicable, except that such limitation shall not apply in the
event that the Company (i) obtains the approval of its stockholders as required
by applicable rules and regulations of the Principal Market for issuances of
securities in excess of the Exchange Cap, or (ii) obtains a written opinion from
outside counsel to the Company that such approval is not required, which opinion
shall be reasonably satisfactory to the Investors. Until such approval or
written opinion is obtained or such action has been taken by the Investors, no
Holder of this Warrant shall be issued, upon exercise of this Warrant, shares of
Series B Preferred Stock in an amount that, when added to all Securities issued
to such Holder, is greater than the product of (x) the Exchange Cap amount
multiplied by (y) a fraction, the numerator of which is the number of Warrant
Shares issuable upon exercise to such Holder pursuant to this Warrant and the
denominator of which is the aggregate amount of all the Warrant Shares issuable
upon exercise to the Holders of all Warrants issued under the Purchase Agreement
(the "CAP ALLOCATION AMOUNT"). In the event that the Holder shall sell or
otherwise transfer any portion of this Warrant, the transferee shall be
allocated a pro rata portion of the Holder's Cap Allocation Amount. In the event
that the Holder shall exercise all of this Warrant into a number of shares of
Series B Preferred Stock that, in the aggregate, is less than the Holder's Cap
Allocation Amount, then the difference between the Holder's Cap Allocation
Amount and the number of shares of Series B Preferred Stock actually issued to
such Holder shall be allocated to the respective Cap Allocation Amounts of the
Investors on a pro rata basis in proportion to the number of Warrant Shares
issuable upon exercise then held by the Investors.

                  4. NO FRACTIONAL SHARES OR SCRIP. No fractional shares or
scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be
entitled to purchase upon such exercise, the Company shall issue one additional
share of Series B Preferred Stock.

                  5. CHARGES, TAXES AND EXPENSES. Issuance of certificates for
shares of Series B Preferred Stock upon the exercise of this Warrant shall be
made without charge to the Holder hereof for any issue or transfer tax or other
incidental expense in respect of the issuance of such certificate, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of the Holder of this Warrant or in such name or names as may
be directed by the Holder of this Warrant; provided, however, that in the event
certificates for shares of Series B Preferred Stock are to be issued in a name
other than the name of the Holder of this Warrant, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder hereof; and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto.

                                       3
<PAGE>

                  6. FURTHER ASSURANCES. The Company will take all action that
may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable shares of stock, free from all taxes,
liens and charges with respect to the issue thereof, on the exercise of all or
any portion of this Warrant from time to time outstanding.

                  7. TRANSFER, DIVISION AND COMBINATION. (a) Subject to
compliance with any applicable securities laws, transfer of this Warrant and all
rights hereunder, in whole or in part, shall be registered on the books of the
Company to be maintained for such purpose, upon surrender of this Warrant at the
principal office of the Company, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or
its agent or attorney and funds sufficient to pay any transfer taxes payable
upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the
name of the assignee or assignees and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be
exercised by a new Holder for the purchase of shares of Series B Preferred Stock
without having a new Warrant issued.

                           (b) This Warrant may be divided or combined with
other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which
new Warrants are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 7(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver
a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice.

                           (c) The Company shall prepare, issue and deliver at
its own expense (other than transfer taxes) the new Warrant or Warrants under
this Section 7.

                           (d) The Company agrees to maintain, at its aforesaid
office, books for the registration and the registration of transfer of the
Warrants.

                  8. NO RIGHTS AS SHAREHOLDER UNTIL EXERCISE. This Warrant does
not entitle the Holder hereof to any voting rights or other rights as a
shareholder of the Company prior to the exercise hereof. Upon the surrender of
this Warrant and the payment of the aggregate Exercise Price, the Warrant Shares
so purchased shall be and be deemed to be issued to such Holder as the record
owner of such shares as of the close of business on the later of the date of
such surrender or payment.

                  9. LOSS, THEFT, DESTRUCTION OR MUTILATION OF WARRANT. The
Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
certificate or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory
to it (which shall include the posting of a bond only if the Holder is not the
purchaser of this Warrant under the Purchase Agreement or an affiliate of such
purchaser), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or
stock certificate of like tenor and dated as of such cancellation, in lieu of
such Warrant or stock certificate.

                  10. SATURDAYS, SUNDAYS, HOLIDAYS, ETC. If the last or
appointed day for the taking of any action or the expiration of any right
required or granted herein shall be a Saturday, Sunday or a legal holiday, then
such action may be taken or such right may be exercised on the next succeeding
day not a Saturday, Sunday or legal holiday.

                                       4
<PAGE>

                 11. ADJUSTMENTS OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.

                           (a) STOCK SPLITS, ETC. The number and kind of
securities purchasable upon the exercise of this Warrant and the Exercise Price
shall be subject to adjustment from time to time upon the happening of any of
the following. In case the Company shall (i) pay a dividend in shares of Series
B Preferred Stock or make a distribution in shares of Series B Preferred Stock
to the holders of its outstanding Series B Preferred Stock, (ii) subdivide its
outstanding shares of Series B Preferred Stock into a greater number of shares
of Series B Preferred Stock, (iii) combine its outstanding shares of Series B
Preferred Stock into a smaller number of shares of Series B Preferred Stock or
(iv) issue any shares of its capital stock in a reclassification of the Series B
Preferred Stock, then the number of Warrant Shares purchasable upon exercise of
this Warrant immediately prior thereto shall be adjusted so that the Holder of
this Warrant shall be entitled to receive the kind and number of Warrant Shares
or other securities of the Company which he would have owned or have been
entitled to receive had such Warrant been exercised in advance thereof. Upon
each such adjustment of the kind and number of Warrant Shares or other
securities of the Company which are purchasable hereunder, the Holder of this
Warrant shall thereafter be entitled to purchase the number of Warrant Shares or
other securities resulting from such adjustment at an Exercise Price per Warrant
Share or other security obtained by multiplying the Exercise Price in effect
immediately prior to such adjustment by the number of Warrant Shares purchasable
pursuant hereto immediately prior to such adjustment and dividing by the number
of Warrant Shares or other securities of the Company resulting from such
adjustment. An adjustment made pursuant to this paragraph shall become effective
immediately after the effective date of such event retroactive to the record
date, if any, for such event.

                           (b) REORGANIZATION, RECLASSIFICATION, MERGER,
CONSOLIDATION OR DISPOSITION OF ASSETS. In case the Company shall reorganize its
capital, reclassify its capital stock, consolidate or merge with or into another
corporation (where the Company is not the surviving corporation or where there
is a change in or distribution with respect to the Series B Preferred of the
Company), or sell, transfer or otherwise dispose of all or substantially all its
property, assets or business to another corporation and, pursuant to the terms
of such reorganization, reclassification, merger, consolidation or disposition
of assets, shares of common stock of the successor or acquiring corporation, or
any cash, shares of stock or other securities or property of any nature
whatsoever (including warrants or other subscription or purchase rights) in
addition to or in lieu of common stock of the successor or acquiring corporation
("OTHER PROPERTY"), are to be received by or distributed to the holders of
Series B Preferred Stock of the Company, then the Holder shall have the right
thereafter to receive, upon exercise of this Warrant, the number of shares of
common stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and Other Property receivable upon or as a result
of such reorganization, reclassification, merger, consolidation or disposition
of assets by a holder of the number of shares of Series B Preferred Stock for
which this Warrant is exercisable immediately prior to such event. In case of
any such reorganization, reclassification, merger, consolidation or disposition
of assets, the successor or acquiring corporation (if other than the Company)
shall expressly assume the due and punctual observance and performance of each
and every covenant and condition of this Warrant to be performed and observed by
the Company and all the obligations and liabilities hereunder, subject to such
modifications as may be deemed appropriate (as determined in good faith by
resolution of the Board of Directors of the Company) in order to provide for
adjustments of shares of Series B Preferred Stock for which this Warrant is
exercisable which shall be as nearly equivalent as practicable to the
adjustments provided for in this Section 11. For purposes of this Section 11,
"common stock of the successor or acquiring corporation" shall include stock of
such corporation of any class which is not preferred as to dividends or assets
over any other class of stock of such corporation and which is not subject to
redemption and shall also include any evidences of indebtedness, shares of stock
or other securities which are convertible into or exchangeable for any such
stock, either immediately or upon the arrival of a

                                       5
<PAGE>

specified date or the happening of a specified event and any warrants or
other rights to subscribe for or purchase any such stock. The foregoing
provisions of this Section 11 shall similarly apply to successive
reorganizations, reclassifications, mergers, consolidations or disposition
of assets.

                           (c) NOMINAL ADJUSTMENT. The Company shall not be
required to make an adjustment in the Exercise Price under this Section 11 if
such adjustment is less that $0.01. However, the Company shall be required to
carry forward on its books all adjustments that would have been made but for
this Section 11(c) and shall take such adjustment into account when making
subsequent adjustments under this Section 11. All calculations under this
Section 11 shall be made to the nearest cent.

                  12. VOLUNTARY ADJUSTMENT BY THE COMPANY. The Company may at
any time during the term of this Warrant, reduce the then current Exercise Price
to any amount and for any period of time deemed appropriate by the Board of
Directors of the Company.

                  13. NOTICE OF ADJUSTMENT. Whenever the number of Warrant
Shares or number or kind of securities or other property purchasable upon the
exercise of this Warrant or the Exercise Price is adjusted, as herein provided,
the Company shall promptly mail by registered or certified mail, return receipt
requested, to the Holder of this Warrant notice of such adjustment or
adjustments setting forth the number of Warrant Shares (and Other Property)
purchasable upon the exercise of this Warrant and the Exercise Price of such
Warrant Shares (and Other Property) after such adjustment, setting forth a brief
statement of the facts requiring such adjustment and setting forth the
computation by which such adjustment was made. Such notice, in the absence of
manifest error, shall be conclusive evidence of the correctness of such
adjustment.

                  14. NOTICE OF CORPORATE ACTION. If at any time:

                           (a) the Company shall take a record of the holders of
its Common Stock or Series B Preferred Stock for the purpose of entitling them
to receive a dividend or other distribution, or any right to subscribe for or
purchase any evidences of its indebtedness, any shares of stock of any class or
any other securities or property, or to receive any other right; or

                           (b) there shall be any capital reorganization of the
Company, any reclassification or recapitalization of the capital stock of the
Company or any consolidation or merger of the Company with, or any sale,
transfer or other disposition of all or substantially all the property, assets
or business of the Company to, another corporation; or

                           (c) there shall be a voluntary or involuntary
dissolution, liquidation or winding up of the Company;

then, in any one or more of such cases, the Company shall give to the Holder
(i) at least 30 days' prior written notice of the date on which a record date
shall be selected for such dividend, distribution or right or for determining
rights to vote in respect of any such reorganization, reclassification,
merger, consolidation, sale, transfer, disposition, liquidation or winding
up, and (ii) in the case of any such reorganization, reclassification,
merger, consolidation, sale, transfer, disposition, dissolution, liquidation
or winding up, at least 30 days' prior written notice of the date when the
same shall take place. Such notice in accordance with the foregoing clause
also shall specify (i) the date on which any such record is to be taken for
the purpose of such dividend, distribution or right, the date on which the
holders of Common Stock or Series B Preferred Stock shall be entitled to any
such dividend, distribution or right, and the amount and character thereof,
and (ii) the date on which any such reorganization, reclassification, merger,
consolidation, sale, transfer, disposition, dissolution, liquidation or
winding up is to take place and the time, if any such time is to be fixed, as
of which the holders of Common Stock or Series B

                                       6
<PAGE>

Preferred Stock shall be entitled to exchange their shares of Common Stock or
Series B Preferred Stock for securities or Other Property deliverable upon
such disposition, dissolution, liquidation or winding up. Each such written
notice shall be sufficiently given if addressed to the Holder at the last
address of the Holder appearing on the books of the Company and delivered in
accordance with Section 16(d).

                  15. AUTHORIZED SHARES.

                           (a) The Company covenants that during the period the
Warrant is outstanding, it will reserve from its authorized and unissued Series
B Preferred Stock a sufficient number of shares to provide for the issuance of
the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such
Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Principal Market
upon which the Common Stock may be listed.

                           (b) The Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate to protect the
rights of the Holder against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any shares of
Common Stock receivable upon the exercise of this Warrant above the amount
payable therefor upon such exercise immediately prior to such increase in par
value, (ii) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
shares of Series B Preferred Stock upon the exercise of this Warrant, and (iii)
use its best efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this Warrant.

                           (c) Upon the request of the the Holder, the Company
will at any time during the period this Warrant is outstanding acknowledge in
writing, in form reasonably satisfactory to the Holder, the continuing validity
of this Warrant and the obligations of the Company hereunder.

                           (d) Before taking any action which would cause an
adjustment reducing the current Exercise Price below the then par value, if any,
of the shares of Series B Preferred Stock issuable upon exercise of the
Warrants, the Company shall take any corporate action which may be necessary in
order that the Company may validly and legally issue fully paid and
non-assessable shares of such Common Stock at such adjusted Exercise Price.

                           (e) Before taking any action which would result in an
adjustment in the number of shares of Series B Preferred Stock for which this
Warrant is exercisable or in the Exercise Price, the Company shall obtain all
such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

                  16. MISCELLANEOUS.

                           (a) JURISDICTION. This Warrant shall be binding upon
any successors or assigns of the Company. This Warrant shall constitute a
contract under the laws of Delaware without

                                       7
<PAGE>

regard to its conflict of law principles or rules, and be subject to
arbitration pursuant to the terms set forth in the Purchase Agreement.

                           (b) RESTRICTIONS. The Holder hereof acknowledges that
the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, will have restrictions upon resale imposed by state and federal
securities laws.

                           (c) NONWAIVER AND EXPENSES. No course of dealing or
any delay or failure to exercise any right hereunder on the part of the Holder
shall operate as a waiver of such right or otherwise prejudice the Holder's
rights, powers or remedies, notwithstanding all rights hereunder terminate on
the Termination Date. If the Company fails to comply with any provision of this
Warrant, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable
attorneys' fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

                           (d) NOTICES. Any notice, request or other document
required or permitted to be given or delivered to the Holder hereof by the
Company shall be delivered in accordance with the notice provisions of the
Purchase Agreement.

                           (e) LIMITATION OF LIABILITY. No provision hereof, in
the absence of affirmative action by the Holder to purchase shares of Series B
Preferred Stock, and no enumeration herein of the rights or privileges of the
Holder hereof, shall give rise to any liability of the Holder for the purchase
price of any Series B Preferred Stock or as a stockholder of the Company,
whether such liability is asserted by the Company or by creditors of the
Company.

                           (f) REMEDIES. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The
Company agrees that monetary damages would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this Warrant and
hereby agrees to waive the defense in any action for specific performance that a
remedy at law would be adequate.

                           (g) SUCCESSORS AND ASSIGNS. Subject to applicable
securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company
and the successors and permitted assigns of the Holder. The provisions of this
Warrant are intended to be for the benefit of all holders from time to time of
this Warrant and shall be enforceable by any such Holder or holder of Warrant
Shares.

                           (h) INDEMNIFICATION. The Company agrees to indemnify
and hold harmless the Holder from and against any liabilities, obligations,
losses, damages, penalties, actions, judgments, suits, claims, costs, attorneys'
fees, expenses and disbursements of any kind which may be imposed upon, incurred
by or asserted against the Holder in any manner relating to or arising out of
any failure by the Company to perform or observe in any material respect any of
its covenants, agreements, undertakings or obligations set forth in this
Warrant; PROVIDED, HOWEVER, that the Company will not be liable hereunder to the
extent that any liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, claims, costs, attorneys' fees, expenses or disbursements are
found in a final non-appealable judgment by a court to have resulted from the
Holder's bad faith or willful misconduct in its capacity as a stockholder or
warrantholder of the Company.

                           (i) AMENDMENT. This Warrant may be modified or
amended or the provisions hereof waived with the written consent of the Company
and the Holder.

                                       8
<PAGE>

                           (j) SEVERABILITY. Wherever possible, each provision
of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited
by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of
such provisions or the remaining provisions of this Warrant.

                           (k) HEADINGS. The headings used in this Warrant are
for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

                            [SIGNATURE PAGE FOLLOWS]

                                       9
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this Warrant to be executed
by its officer thereunto duly authorized.

Dated:  April ___, 2001

                                          INTERACTIVE TELESIS INC.

                                          By:__________________________________
                                              Name:____________________________
                                              Title:___________________________

                                       10
<PAGE>

                               NOTICE OF EXERCISE

To:   [Transfer Agent]

                  (1) The undersigned hereby elects to purchase ________ shares
of Series B Preferred Stock of Interactive Telesis Inc. pursuant to the terms of
the attached Warrant, and [ ] tenders herewith payment of the exercise price in
full OR [ ] tenders the Warrant for cashless exercise, together with all
applicable transfer taxes, if any.

                  (2) Calculation of cashless exercise value, if applicable:___
_______________________________________________________________________________.

                  (3) Please issue a certificate or certificates representing
said shares of Series B Preferred Stock in the name of the undersigned or in
such other name as is specified below:

                                    _______________________________
                                    (Name)

                                    _______________________________
                                    (Address)

                                    _______________________________

Dated:_____________________, _____

                                              _________________________________
                                              Signature

                                       11
<PAGE>

                                 ASSIGNMENT FORM

                    (To assign the foregoing Warrant, execute
                    this form and supply required information.
                   Do not use this form to exercise the Warrant.)

                  FOR VALUE RECEIVED, the foregoing Warrant and all rights
evidenced thereby are hereby assigned to

_______________________________________________ whose address is

_______________________________________________________________.

_______________________________________________________________

                                               Dated: ______________, _______

                           Holder's Signature: _____________________________

                           Holder's Address:   _____________________________

                                               _____________________________

Signature Guaranteed:  ___________________________________________

NOTE: The signature to this Assignment Form must correspond with the name as it
appears on the face of the Warrant, without alteration or enlargement or any
change whatsoever, and must be guaranteed by a bank or trust company. Officers
of corporations and those acting in an fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing
Warrant.

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}]]